Psychopharmacological treatment of psychotic children. A survey

Area of Science:

• Child and Adolescent Psychiatry
• Developmental Neuroscience
• Clinical Psychology

Background:

• Psychotic disorders in children are complex and require specialized treatment approaches.
• Infantile autism is a developmental disorder that may present with psychotic features.
• The efficacy and safety of psychopharmacological interventions in pediatric populations are areas of ongoing research.

Purpose of the Study:

• To review controlled investigations on the psychopharmacological treatment of psychotic children.
• To evaluate the potential benefits of medication for children with infantile autism and other childhood psychoses.
• To highlight considerations for treatment, including age-related efficacy and potential adverse effects.

Main Methods:

• Systematic review of controlled studies on psychopharmacological treatments for psychotic children.
• Analysis of data concerning the impact of medication on psychotic symptoms and learning.
• Examination of the prevalence and treatment of schizophrenia and manic-depressive psychosis in childhood.

Main Results:

• Children with infantile autism may benefit from psychopharmacological treatment, particularly after age 7.
• Medication can facilitate learning by inhibiting psychotic preoccupations and idiosyncratic reactions.
• Schizophrenia and manic-depressive psychosis are rare in childhood but treated similarly to adults, with caution regarding imipramine toxicity.

Conclusions:

• Psychopharmacological interventions show potential for managing psychotic symptoms in specific pediatric populations.
• Age is a critical factor in treatment response for children with infantile autism.
• Adverse effects, such as those from imipramine, necessitate careful clinical monitoring in pediatric psychopharmacology.